- Home
- ACTG vs CDXC Comparison
ACTG vs CDXC Comparison
Compare ACTG & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTG
- CDXC
- Stock Information
- Founded
- ACTG 1993
- CDXC 1999
- Country
- ACTG United States
- CDXC United States
- Employees
- ACTG N/A
- CDXC N/A
- Industry
- ACTG Multi-Sector Companies
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- ACTG Miscellaneous
- CDXC Health Care
- Exchange
- ACTG Nasdaq
- CDXC Nasdaq
- Market Cap
- ACTG 414.8M
- CDXC 415.5M
- IPO Year
- ACTG 1996
- CDXC N/A
- Fundamental
- Price
- ACTG $4.44
- CDXC $6.09
- Analyst Decision
- ACTG Strong Buy
- CDXC Strong Buy
- Analyst Count
- ACTG 1
- CDXC 2
- Target Price
- ACTG $7.00
- CDXC $8.00
- AVG Volume (30 Days)
- ACTG 203.4K
- CDXC 431.2K
- Earning Date
- ACTG 03-13-2025
- CDXC 03-05-2025
- Dividend Yield
- ACTG N/A
- CDXC N/A
- EPS Growth
- ACTG N/A
- CDXC N/A
- EPS
- ACTG 0.39
- CDXC 0.02
- Revenue
- ACTG $165,779,000.00
- CDXC $91,668,000.00
- Revenue This Year
- ACTG N/A
- CDXC $18.64
- Revenue Next Year
- ACTG $84.79
- CDXC $20.72
- P/E Ratio
- ACTG $11.39
- CDXC $311.55
- Revenue Growth
- ACTG 261.08
- CDXC 9.95
- 52 Week Low
- ACTG $3.78
- CDXC $1.36
- 52 Week High
- ACTG $5.74
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- ACTG 54.57
- CDXC 57.85
- Support Level
- ACTG $4.31
- CDXC $5.17
- Resistance Level
- ACTG $4.44
- CDXC $5.52
- Average True Range (ATR)
- ACTG 0.10
- CDXC 0.26
- MACD
- ACTG 0.02
- CDXC 0.10
- Stochastic Oscillator
- ACTG 87.50
- CDXC 86.92
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, significant capital base, and deep industry relationships to drive value. Acacia evaluates opportunities based on the attractiveness of the underlying cash flows, without regard to a specific investment horizon. Acacia operates its businesses based on three key principles of people, process, and performance and has built a management team with demonstrated expertise in research, transactions and execution, and operations and management.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.